QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) Prices $13.8 Million Public Offering
BriaCell Therapeutics (Nasdaq: BCTX, BCTXZ) (TSX: BCT) announced the pricing of an underwritten public offering of 3,066,666 units at $4.50 per unit for gross proceeds of approximately $13.8 million. Each unit includes one common share or pre-funded warrant and one warrant exercisable at $5.25 per share. The offering, led by ThinkEquity, is expected to close on April 28, 2025, subject to customary conditions. BriaCell plans to use the net proceeds for working capital, corporate purposes and advancing business objectives. To view the full article, visit https://ibn.fm/YUyxu About BriaCell Therapeutics BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to…
